Developer docs
API playgroundTry for free, no card

Search company profiles

Immunovant

Full company profile

uuid0002qbm

Namestring
Immunovant
Legal namestring
Immunovant, Inc.
Websiteurl
immunovant.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune disease. The company's core technology targets the FcRn pathway, which regulates IgG antibody recycling and levels, with the goal of producing disease-modifying effects across multiple IgG-mediated autoimmune conditions. Immunovant is incorporated in Delaware, headquartered in New York, and maintains operational offices in Durham, North Carolina and Basel, Switzerland (Immunovant Sciences GmbH); it employs between 251 and 500 people and operates as a majority-owned subsidiary of Roivant Sciences, which holds approximately 64.65% ownership as of December 2025.

The company's pipeline centers on IMVT-1402 (imeroprubart), a next-generation FcRn inhibitor being advanced through registrational trials for at least six indications: Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease, refractory rheumatoid arthritis, and cutaneous lupus. An earlier FcRn inhibitor, batoclimab, was discontinued after Phase 3 trials in thyroid eye disease failed to meet the primary endpoint in April 2026. IMVT-1402 demonstrated 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in a Phase 2b trial of 165 highly refractory rheumatoid arthritis patients, and topline data for Graves' disease is expected in 2027. Target markets are substantial: Graves' disease affects an estimated 880,000 US patients with analyst-projected $1 billion-plus US sales potential, the myasthenia gravis market is projected to surpass $16 billion by 2036 across seven major markets, and the CIDP market was valued at approximately $1.78 billion in 2023.

Immunovant has no approved products and does not currently generate revenue from product sales; the company is funded almost entirely by equity capital from public markets, private placements, and repeated strategic investments from parent Roivant Sciences. The cumulative capital base includes a $75 million offering in October 2022, a $450 million public offering in September 2023, a $200 million Roivant investment in February 2024, a $450 million private placement in January 2025, and a $550 million common stock financing in December 2025 — the latter explicitly earmarked to fund the potential launch of IMVT-1402 in Graves' disease. As of May 2026, Immunovant reported $902.1 million in cash with no debt, a Q3 FY2025 net loss of $110.6 million, and a market capitalization of approximately $5.9 billion. Go-to-market activity is currently limited to investor-focused channels (SEC filings, press releases, corporate investor relations) consistent with pre-revenue clinical-stage status; commercial distribution infrastructure has not yet been established.

Short descriptiontext

Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies, with lead candidate IMVT-1402 in registrational trials for multiple autoimmune diseases including Graves' disease, myasthenia gravis, CIDP, and refractory rheumatoid arthritis. The pre-revenue company is majority-owned by Roivant Sciences.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
FcRn inhibitor therapies, monoclonal antibody drugs, autoimmune disease treatments, clinical-stage biopharmaceuticals, IgG antibody therapies
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune diseases. The company's lead candidate IMVT-1402 (imeroprubart) is being advanced through registrational trials across multiple indications including Graves' disease, myasthenia gravis, CIDP, Sjögren's disease, and refractory rheumatoid arthritis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in 165 highly refractory RA patients
+2 more records
Product overview1 text field

Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies for autoimmune diseases. The company's core product portfolio centers on IMVT-1402 (imeroprubart), a next-generation FcRn inhibitor currently in registrational trials for multiple indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus. The company previously advanced batoclimab, an earlier FcRn inhibitor, but discontinued its development after Phase 3 failures in thyroid eye disease. Both drug candidates target IgG antibodies involved in inflammation, leveraging the FcRn pathway to reduce pathogenic IgG levels.

Product and service1 record
1IMVT-1402 (imeroprubart)
CategoryBiopharmaceutical - FcRn Inhibitor
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

HanAll Biopharma is the partner for batoclimab development. Immunovant is reviewing future development plans for batoclimab with HanAll following Phase 3 failures in thyroid eye disease.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

J&J is advancing nipocalimab, an FcRn inhibitor being studied across multiple autoimmune indications including MG and CIDP, and brings large pharma commercial capabilities and capital that exceed Immunovant's.

TypeBroad incumbent
Description

Takeda has built a substantial rare-disease and immunology franchise through Shire and subsequent deals, making it a relevant peer for specialty autoimmune commercialization in MG and CIDP-adjacent indications.

TypeBroad incumbent
Description

Roche acquired Telavant from Roivant for $7.25B and is a major autoimmune and rare-disease player. It is comparable both as a competitor in adjacent indications and as a benchmark acquirer of late-stage autoimmune assets.

TypeDirect peer
Description

argenx is the lead FcRn inhibitor company, with efgartigimod (Vyvgart) approved in myasthenia gravis and CIDP. It is the most direct competitive peer, addressing the same FcRn mechanism and overlapping indications.

TypeDirect peer
Description

UCB markets rozanolixizumab (Rystiggo), an FcRn inhibitor approved for myasthenia gravis, and is advancing additional FcRn programs. It competes head-to-head with Immunovant in the same autoimmune indications.

TypeEmerging player
Description

Vertex is a profitable mid-to-large cap biotech transitioning into specialty/autoimmune adjacencies; it provides a benchmark for late-stage biotech capital allocation and pipeline diversification.

TypeEmerging player
Description

BioMarin is a mid-cap rare-disease biotech focused on genetic and specialty conditions, comparable in stage and scale to Immunovant for pipeline valuation and rare-disease commercialization.

TypeBroad incumbent
Description

Sanofi is a global leader in immunology (Dupixent) and rare autoimmune diseases, providing an incumbent reference point for specialty autoimmune commercialization at scale.

TypeBroad incumbent
Description

Through its Alexion rare-disease franchise, AstraZeneca is a major player in autoimmune neurology and rare immunology and has invested in next-generation FcRn and related modalities.

TypeBroad incumbent
Description

Amgen's acquisition of Horizon Therapeutics brought Tepezza for thyroid eye disease and a rare autoimmune commercial infrastructure. It is a relevant comparable for autoimmune market access and commercial execution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunovant

Biopharmaceuticalsimmunovant.com

Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies, with lead candidate IMVT-1402 in registrational trials for multiple autoimmune diseases including Graves' disease, myasthenia gravis, CIDP, and refractory rheumatoid arthritis. The pre-revenue company is majority-owned by Roivant Sciences.

What Immunovant does

Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune disease. The company's core technology targets the FcRn pathway, which regulates IgG antibody recycling and levels, with the goal of producing disease-modifying effects across multiple IgG-mediated autoimmune conditions. Immunovant is incorporated in Delaware, headquartered in New York, and maintains operational offices in Durham, North Carolina and Basel, Switzerland (Immunovant Sciences GmbH); it employs between 251 and 500 people and operates as a majority-owned subsidiary of Roivant Sciences, which holds approximately 64.65% ownership as of December 2025.

The company's pipeline centers on IMVT-1402 (imeroprubart), a next-generation FcRn inhibitor being advanced through registrational trials for at least six indications: Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease, refractory rheumatoid arthritis, and cutaneous lupus. An earlier FcRn inhibitor, batoclimab, was discontinued after Phase 3 trials in thyroid eye disease failed to meet the primary endpoint in April 2026. IMVT-1402 demonstrated 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in a Phase 2b trial of 165 highly refractory rheumatoid arthritis patients, and topline data for Graves' disease is expected in 2027. Target markets are substantial: Graves' disease affects an estimated 880,000 US patients with analyst-projected $1 billion-plus US sales potential, the myasthenia gravis market is projected to surpass $16 billion by 2036 across seven major markets, and the CIDP market was valued at approximately $1.78 billion in 2023.

Immunovant has no approved products and does not currently generate revenue from product sales; the company is funded almost entirely by equity capital from public markets, private placements, and repeated strategic investments from parent Roivant Sciences. The cumulative capital base includes a $75 million offering in October 2022, a $450 million public offering in September 2023, a $200 million Roivant investment in February 2024, a $450 million private placement in January 2025, and a $550 million common stock financing in December 2025 — the latter explicitly earmarked to fund the potential launch of IMVT-1402 in Graves' disease. As of May 2026, Immunovant reported $902.1 million in cash with no debt, a Q3 FY2025 net loss of $110.6 million, and a market capitalization of approximately $5.9 billion. Go-to-market activity is currently limited to investor-focused channels (SEC filings, press releases, corporate investor relations) consistent with pre-revenue clinical-stage status; commercial distribution infrastructure has not yet been established.

Immunovant firmographics

Firmographics
Name
Immunovant
Legal name
Immunovant, Inc.
Website
https://immunovant.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
251–500 employees
Short description
Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies, with lead candidate IMVT-1402 in registrational trials for multiple autoimmune diseases including Graves' disease, myasthenia gravis, CIDP, and refractory rheumatoid arthritis. The pre-revenue company is majority-owned by Roivant Sciences.
Ownership category
akta.pro rank

Immunovant industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • FcRn inhibitor therapies
  • Monoclonal antibody drugs
  • Autoimmune disease treatments
  • Clinical-stage biopharmaceuticals
  • IgG antibody therapies

Where Immunovant is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Immunovant business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels4 records

Immunovant product offering

Product offering

Core offering

Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune diseases. The company's lead candidate IMVT-1402 (imeroprubart) is being advanced through registrational trials across multiple indications including Graves' disease, myasthenia gravis, CIDP, Sjögren's disease, and refractory rheumatoid arthritis.

Product overview

Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies for autoimmune diseases. The company's core product portfolio centers on IMVT-1402 (imeroprubart), a next-generation FcRn inhibitor currently in registrational trials for multiple indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus. The company previously advanced batoclimab, an earlier FcRn inhibitor, but discontinued its development after Phase 3 failures in thyroid eye disease. Both drug candidates target IgG antibodies involved in inflammation, leveraging the FcRn pathway to reduce pathogenic IgG levels.

Differentiator

Problem solved

Functional benefit

Products and services

  • IMVT-1402 (imeroprubart)

Quantifiable outcome

  • 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in 165 highly refractory RA patients
  • +2 more outcomes

Companies that use Immunovant

Customer profile

Segments5 records

Ideal customer profiles2 records

Immunovant technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Immunovant partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HanAll BiopharmaminorStrategic or Co-development PartnerHanAll Biopharma is the partner for batoclimab development. Immunovant is reviewing future development plans for batoclimab with HanAll following Phase 3 failures in thyroid eye disease.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Immunovant competitors and assessment

Company assessment

Broad incumbents

  • Johnson & Johnson: J&J is advancing nipocalimab, an FcRn inhibitor being studied across multiple autoimmune indications including MG and CIDP, and brings large pharma commercial capabilities and capital that exceed Immunovant's.
  • Takeda: Takeda has built a substantial rare-disease and immunology franchise through Shire and subsequent deals, making it a relevant peer for specialty autoimmune commercialization in MG and CIDP-adjacent indications.
  • Roche: Roche acquired Telavant from Roivant for $7.25B and is a major autoimmune and rare-disease player. It is comparable both as a competitor in adjacent indications and as a benchmark acquirer of late-stage autoimmune assets.
  • Sanofi: Sanofi is a global leader in immunology (Dupixent) and rare autoimmune diseases, providing an incumbent reference point for specialty autoimmune commercialization at scale.
  • AstraZeneca (Alexion): Through its Alexion rare-disease franchise, AstraZeneca is a major player in autoimmune neurology and rare immunology and has invested in next-generation FcRn and related modalities.
  • Amgen (Horizon Therapeutics): Amgen's acquisition of Horizon Therapeutics brought Tepezza for thyroid eye disease and a rare autoimmune commercial infrastructure. It is a relevant comparable for autoimmune market access and commercial execution.

Direct peers

  • argenx: argenx is the lead FcRn inhibitor company, with efgartigimod (Vyvgart) approved in myasthenia gravis and CIDP. It is the most direct competitive peer, addressing the same FcRn mechanism and overlapping indications.
  • UCB: UCB markets rozanolixizumab (Rystiggo), an FcRn inhibitor approved for myasthenia gravis, and is advancing additional FcRn programs. It competes head-to-head with Immunovant in the same autoimmune indications.

Emerging players

  • Vertex Pharmaceuticals: Vertex is a profitable mid-to-large cap biotech transitioning into specialty/autoimmune adjacencies; it provides a benchmark for late-stage biotech capital allocation and pipeline diversification.
  • BioMarin Pharmaceutical: BioMarin is a mid-cap rare-disease biotech focused on genetic and specialty conditions, comparable in stage and scale to Immunovant for pipeline valuation and rare-disease commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Immunovant social profiles

Digital presence

Immunovant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunovant leadership team

Management profile

Number of profiles

Profiles14 records

Immunovant funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunovant M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunovant

What does Immunovant do?

Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune diseases. The company's lead candidate IMVT-1402 (imeroprubart) is being advanced through registrational trials across multiple indications including Graves' disease, myasthenia gravis, CIDP, Sjögren's disease, and refractory rheumatoid arthritis.

Is Immunovant a public or private company?

Immunovant is a public company. It is classified as public and is currently operating.

When was Immunovant founded?

Immunovant was founded in 2018. It employs 251 to 500 people.

Where is Immunovant based?

Immunovant is headquartered in New York, United States, in the North America region.

Who are Immunovant's main competitors?

Broad incumbents on record are Johnson & Johnson, Takeda, Roche, Sanofi, AstraZeneca (Alexion) and Amgen (Horizon Therapeutics). Direct peers are argenx and UCB. Emerging players are Vertex Pharmaceuticals and BioMarin Pharmaceutical.

Does Immunovant have an API?

No public API is recorded for Immunovant.

What industry is Immunovant in?

Immunovant's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market News545,730 Shares of Immunovant, Inc. $IMVT Bought by Fisher Asset Management LLCFisher Asset Management bought 545,730 Immunovant shares in Q3, valued at about $18.4 million, giving it a 0.26% stake. Analysts have a consensus 'Moderate Buy' rating with an average target price of $44.60. The stock opened at $34.18, and insiders sold 27,430 shares in the last quarter.Simply Wall StWhy Immunovant (IMVT) Is Up 15.1% And What's NextImmunovant reported a Q2 net loss of $97.25 million and a basic loss per share of $0.47, while releasing positive topline data for IMVT-1402 in rheumatoid arthritis and early LISRAYA revenue. The company filed a $150 million at-the-market equity program and a shelf registration to support development and commercial expansion.Investing.comImmunovant surges on trial results, earnings beatImmunovant shares rose 11.7% after its drug IMVT-1402 met the primary endpoint in a rheumatoid arthritis trial, with an ACR20 response of 92.5% versus 75.6% for placebo. The company posted a Q2 adjusted loss of -$0.47 per share, beating estimates of -$0.74, and plans FDA discussions later this year.MarketScreenerImmunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026Immunovant reported a Q2 net loss of $97.25 million, down from $126.5 million a year ago, and a six-month net loss of $250.47 million, down from $247.12 million. Basic and diluted loss per share from continuing operations were $0.47 and $1.22, respectively, compared to $0.73 and $1.43 a year ago.Seeking AlphaAt a glance: Stocks gapping up premarketStock index futures rose premarket Monday despite pressure from Nvidia. Immunovant led gains with a 16.3% jump, followed by Kodiak Gas Services at 8.2%, QXO at 6%, Roivant Sciences at 5.5%, and NRG Energy at 5.3%.Simply Wall StImmunovant (IMVT) Jumped, What Is Driving Attention Today?Immunovant reported that its IMVT-1402 antibody met the primary endpoint in a Phase 2 trial for difficult-to-treat rheumatoid arthritis, with plans for FDA discussions. The stock jumped 7.54% in one day, while analysts see a fair value of $48.07, implying undervaluation. The company remains pre-revenue, so setbacks could challenge the narrative.Quiver QuantitativeIMMUNOVANT ($IMVT) Releases Q2 2027 Earnings | IMVT Stock NewsIMMUNOVANT reported Q2 2027 earnings of -$0.47 per share, beating estimates of -$0.75 by $0.28, with revenue of $0. Insiders sold 34 times in the past six months, and 109 institutional investors added shares while 94 reduced positions. Analysts have set a median price target of $43.0.Investing.comImmunovant CFO Tiago Girao sells $188,271 in sharesImmunovant CFO Tiago Girao sold 6,606 shares on October 28, 2026, for $188,271, a sell-to-cover transaction for tax withholding on vested RSUs. The sale was mandatory under company policy, and he holds 234,192 shares after the transaction.MarketBeatImmunovant, Inc. (IMVT) - What Are Investment Firms Saying About This Stock?Immunovant shares have an average analyst rating of Moderate Buy with a $44 target. The company missed Q2 EPS estimates at -$0.75 versus -$0.63 expected, while revenue met expectations. CEO Eric Venker sold 3,506 shares in October.Investing.comImmunovant CTO Jay Stout sells $75,099 in sharesImmunovant CTO Jay Stout sold 2,595 shares on October 21, 2026, at $28.94, totaling $75,099, to cover tax withholding from 6,250 vested RSUs. The stock trades at $28.41, up 50% over the past year. H.C. Wainwright and Cantor Fitzgerald maintain Buy and Overweight ratings, respectively.